GE HealthCare Launches AI-Powered Prostate Volume Assist for Ultrasound
Featuring automated one-click functionality for capturing prostate volume, the AI-enabled software may help shorten workflows for prostate imaging, biopsies, and ultrasound-guided procedures.
An emerging artificial intelligence software may enable clinicians to quickly obtain automated measurements of prostate volume.
With the launch of Prostate Volume Assist, clinicians can ascertain prostate measurements and calculations with one click, according to GE HealthCare, the manufacturer of the software. The company said the Prostate Volume Assist can be beneficial with prostate imaging and ultrasound-guided procedures.
With the launch of Prostate Volume Assist, clinicians can ascertain prostate measurements and calculations with one click, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
“Normally, clinicians determine prostate volume through a manual, repetitive process that requires measuring multiple dimensions and applying a mathematical formula,” said Fredrik Gran, head of innovation, surgical visualization and guidance, ultrasound at GE HealthCare. “Prostate Volume Assist uses artificial intelligence to automate this process with a single click, and yield results in less than two seconds. This technology provides an added level of support for (clinicians) to improve efficiencies in the workflow and enable precision care.”
GE HealthCare noted that Prostate Volume Assist will be accessible via the company’s bkActiv, bk3000/5000 and bkSpecto ultrasound modalities.
Recent Videos
Related Content
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025Article
In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
